Recent advances in the development of methyltransferase (MTase) inhibitors against (re)emerging arboviruses diseases dengue and Zika.
Dengue
Drug treatment
Inhibitors
Methyltransferase
Mosquito-borne viruses
Re-emerging viral diseases
Zika
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Apr 2023
05 Apr 2023
Historique:
received:
23
11
2022
revised:
14
03
2023
accepted:
14
03
2023
medline:
14
4
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
Emerging and/or re-emerging viral diseases such as dengue and Zika are a worldwide concern. Therefore, new antiviral therapeutics are necessary. In this sense, a non-structural protein with methyltransferase (MTase) activity is an attractive drug target because it plays a crucial role in dengue and Zika virus replication. Different drug strategies such as virtual screening, molecular docking, and molecular dynamics have identified new inhibitors that bind on the MTase active site. Therefore, in this review, we analyze MTase inhibitors, including S-adenosyl-L-methionine (SAM), S-adenosyl-l-homocysteine (SAH) and guanosine-5'-triphosphate (GTP) analogs, nitrogen-containing heterocycles (pyrimidine, adenosine, and pyridine), urea derivatives, and natural products. Advances in the design of MTase inhibitors could lead to the optimization of a possible single or broad-spectrum antiviral drug against dengue and Zika virus.
Identifiants
pubmed: 36958266
pii: S0223-5234(23)00256-8
doi: 10.1016/j.ejmech.2023.115290
pii:
doi:
Substances chimiques
Viral Nonstructural Proteins
0
Antiviral Agents
0
Methyltransferases
EC 2.1.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
115290Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Gildardo Rivera reports financial support was provided by Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional. Antonio moreno-herrera reports a relationship with AstraZeneca Pharmaceuticals LP that includes: employment. None.